Exact Sciences of Madison, Wisconsin is on a mission to eradicate colorectal cancer. In August 2014, the company received FDA approval for the first test of its kind, Cologuard, a noninvasive stool DNA-based colorectal cancer screening test that requires no prior bowel preparation or dietary restrictions. FDA approval followed a largescale clinical trial, involving 10,000 patients, in which Cologuard found 92% of curable stage cancers, as well as 69% of high-risk pre-cancers—those most likely to develop into cancer.1
Potential to Greatly Increase Screening Compliance
A screening test able to detect colon cancer at its earliest stage is critically important; most people understand that early detection saves lives. Yet many put off getting a screening colonoscopy despite knowing its importance. So what’s the best way to help people overcome their natural resistance? Simple, make screening easy. And that, says Cara Tucker, Senior Manager, Marketing Communications, Exact Sciences, is one of the major advantages of Cologuard, which is used in the privacy of the patient’s own home.